Bao, Chunyang http://orcid.org/0000-0001-7962-346X
Tourdot, Richard W.
Brunette, Gregory J. http://orcid.org/0000-0002-3829-9031
Stewart, Chip
Sun, Lili
Baba, Hideo http://orcid.org/0000-0002-3474-2550
Watanabe, Masayuki
Agoston, Agoston T.
Jajoo, Kunal
Davison, Jon M.
Nason, Katie S.
Getz, Gad http://orcid.org/0000-0002-0936-0753
Wang, Kenneth K.
Imamura, Yu
Odze, Robert http://orcid.org/0000-0001-7910-8273
Bass, Adam J.
Stachler, Matthew D. http://orcid.org/0000-0003-0958-0286
Zhang, Cheng-Zhong http://orcid.org/0000-0001-8825-7158
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K22CA216319)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (K08DK109209)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (U54CA163060)
Article History
Received: 1 August 2023
Accepted: 18 September 2023
First Online: 4 October 2023
Competing interests
: A.J.B. had received research funding from Bayer, Merck, and Novartis, was a consultant to Earli and HelixNano, a co-founder of Signet Therapeutics, and is now an employee of the Novartis Institutes for Biomedical Research. C.-Z.Zhang co-founded and serves as a scientific advisor to Pillar Biosciences. J.M.D. has received consulting income from Castle Biosciences. The remaining authors declare no competing interests.